Concerns on the use of chromium in type 2 diabetes mellitus; needs to conduct major meta-analysis

International Journal of Pharmacology

Volumn 8, Issue 6, 2012, Pages 470-472

  Farshchi, Amir ^a   Nikfar, Shekoufeh ^a,b   Abdollahi, Mohammad ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CHOLESTEROL; CHROMIUM CHLORIDE; CHROMIUM PICOLINATE; EXENDIN 4; GLUCOKINASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INSULIN RECEPTOR; PLACEBO; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ANTIOXIDANT ACTIVITY; ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIET SUPPLEMENTATION; DIET THERAPY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE COST; HUMAN; INCIDENCE; INSULIN SENSITIVITY; IRAN; LIFESTYLE MODIFICATION; LIPID METABOLISM; META ANALYSIS (TOPIC); METHODOLOGY; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR UPREGULATION; SYSTEMATIC REVIEW (TOPIC); WEIGHT REDUCTION;

EID: 84866095707     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2012.470.472     Document Type: Article

References (25)

1. Ali, A., Y. Ma, J. Reynolds, J.P. Wise, S.E. Inzucchi and D.L. Katz, 2011. Chromium effects on glucose tolerance and insulin sensitivity in persons at risk for diabetes mellitus. Endocr. Pract., 17: 16-25.
2. Anderson, R.A., 1998. Chromium, glucose intolerance and diabetes. J. Am. Coll. Nutr., 17: 548-555.
3. Anderson, R.A., N.A. Bryden and M.M. Polansky, 1997. Lack of toxicity of chromium chloride and chromium picolinate in rats. J. Am. Coll. Nutr., 16: 273-279.
4. Azimi-Nezhad, M., M. Ghayour-Mobarhan, M.R. Parizadeh, M. Safarian and H. Esmaeili et al., 2008. Prevalence of type 2 diabetes mellitus in Iran and its relationship with gender, urbanisation, education, marital status and occupation. Singapore Med. J., 49: 571-576.
5. Balk, E.M., A. Tatsioni, A.H. Lichtenstein, J. Lau and A.G. Pittas, 2007. Effect of chromium supplementation on glucose metabolism and lipids: A systematic review of randomized controlled trials. Diabetes Care, 30: 2154-2163.
6. Cefalu, W.T., J. Rood, P. Pinsonat, J. Qin and O. Sereda et al., 2010. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism, 59: 755-762.
7. Cheng, H.H., M.H. Lai, W.C. Hou and C.L. Huang, 2004. Antioxidant effects of chromium supplementation with type 2 diabetes mellitus and euglycemic subjects. J. Agric. Food. Chem., 52: 1385-1389.
8. Davis, C.M. and J.B. Vincent, 1997. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry, 36: 4382-4385.
9. FDA, 2005. Qualified health claims: Letter of enforcement discretion-Chromium picolinate and insulin resistance (docket no. 2004Q-0144). U.S. Food and Drug Administration. http://www.fda.gov/Food/LabelingNutrition/LabelClaims/QualifiedHealthClaims/ucm073017.htm.
10. Fuhr Jr., J.P., H. He, N. Goldfarb and D.B. Nash, 2005. Use of chromium picolinate and biotin in the management of type 2 diabetes: An economic analysis. Dis. Manag., 8: 265-275.
11. Hao, C., J. Hao, W. Wang, Z. Han and G. Li et al., 2011. Insulin sensitizing effects of oligomannuronate-chromium (III) complexes in C2C12 skeletal muscle cells. PLoS One, Vol. 6
12. Hosseini, A. and M. Abdollahi, 2012. It is time to formulate an antioxidant mixture for management of diabetes and its complications: Notice for pharmaceutical industries. Int. J. Pharmacol., 8: 60-61.
13. Janson, M., 2006. Orthomolecular medicine: The therapeutic use of dietary supplements for anti-aging. Clin. Interv. Aging, 1: 261-265.
14. Javanbakht, M., H.R. Baradaran, A. Mashayekhi, A.A. Haghdoost, M.E. Khamseh, E. Kharazmi and A. Sadeghi, 2011. Cost-of-illness analysis of type 2 diabetes mellitus in Iran. PLoS One, Vol. 6.
15. Martin, J., Z.Q. Wang, X.H. Zhang, D. Wachtel, J. Volaufova, D.E. Matthews and W.T. Cefalu, 2006. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with type 2 diabetes. Diabetes Care, 29: 1826-1832.
16. Mertz, W., C.O. Abernathy and S.S. Olin, 1994. Risk Assessment of Essential Elements. IISI Press, Washington, DC., pp: 19-38.
17. Mostafalou, S. and M. Abdollahi, 2012. The role of environmental pollution of pesticides in human diabetes. Int. J. Pharmacol., 8: 139-140.
18. National Research Council., 1989. Recommended Dietary Allowance. 10th Edn., National Academy Press, Washington, DC., USA.
19. Nikfar, S., M. Khatibi, A. Abdollahi-Asl and M. Abdollahi, 2011. Cost and utilization study of antidotes: An Iranian experience. Int. J. Pharmacol., 7: 46-49.
20. Psaltopoulou, T., I. Ilias and M. Alevizaki, 2010. The role of diet and lifestyle in primary, secondary and tertiary diabetes prevention: A review of meta-analyses. Rev. Diabet. Stud., 7: 26-35.
21. Rahimi, R., S. Nikfar, B. Larijani and M. Abdollahi, 2005. A review on the role of antioxidants in the management of diabetes and its complications. Biomed. Pharmacother., 59: 365-373.
22. Salari, P., S. Nikfar and M. Abdollahi, 2011. No superiority of exenatide over insulin in diabetic patients in terms of weight reduction or incidence of adverse effects: A meta-analysis. Int. J. Pharmacol., 7: 749-756.
23. Sharma, S., R.P. Agrawal, M. Choudhary, S. Jain, S. Goyal and V. Agarwal, 2011. Beneficial effect of chromium supplementation on glucose, HbA1C and lipid variables in individuals with newly onset type-2 diabetes. J. Trace. Elem. Med. Biol., 25: 149-153.
24. Vincent, J.B., 2000. Quest for the molecular mechanism of chromium action and its relationship to diabetes. Nutr. Rev., 58: 67-72.
25. Wang, Z.Q. and W.T. Cefalu, 2010. Current concepts about chromium supplementation in type 2 diabetes and insulin resistance. Curr. Diab. Rep., 10: 145-151.